HC Wainwright began coverage on shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) in a research note issued to investors on Friday. The brokerage set a “buy” rating and a $4.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 81.82% from the stock’s previous close.

Several other brokerages have also weighed in on BDSI. Zacks Investment Research lowered BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research report on Wednesday, February 8th. FBR & Co set a $5.00 target price on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Thursday, February 2nd. Roth Capital set a $5.00 target price on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Wednesday, March 22nd. ValuEngine raised BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Friday, May 19th. Finally, Janney Montgomery Scott reaffirmed a “buy” rating and issued a $3.00 target price on shares of BioDelivery Sciences International in a research report on Monday, March 20th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $3.71.

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International (NASDAQ:BDSI) traded up 7.955% during mid-day trading on Friday, reaching $2.375. The company had a trading volume of 461,258 shares. BioDelivery Sciences International has a 12 month low of $1.50 and a 12 month high of $3.10. The firm’s market capitalization is $131.40 million. The stock’s 50-day moving average is $1.87 and its 200 day moving average is $1.89.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings results on Monday, May 15th. The specialty pharmaceutical company reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.49. The firm had revenue of $29.48 million for the quarter, compared to analyst estimates of $27.07 million. BioDelivery Sciences International had a negative return on equity of 309.49% and a negative net margin of 93.61%. On average, analysts predict that BioDelivery Sciences International will post $0.20 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/05/26/biodelivery-sciences-international-inc-bdsi-coverage-initiated-at-hc-wainwright.html.

In related news, CEO Mark A. Sirgo sold 110,895 shares of the stock in a transaction on Friday, March 31st. The stock was sold at an average price of $1.90, for a total value of $210,700.50. Following the completion of the sale, the chief executive officer now directly owns 1,670,157 shares in the company, valued at $3,173,298.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 112,345 shares of company stock valued at $213,456 over the last quarter. Company insiders own 9.00% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Baker BROS. Advisors LP acquired a new stake in shares of BioDelivery Sciences International during the third quarter worth $567,000. Oxford Asset Management boosted its position in BioDelivery Sciences International by 280.8% in the fourth quarter. Oxford Asset Management now owns 107,945 shares of the specialty pharmaceutical company’s stock worth $189,000 after buying an additional 79,599 shares during the period. Stonepine Capital Management LLC bought a new position in BioDelivery Sciences International during the fourth quarter worth about $4,551,000. Broadfin Capital LLC boosted its position in BioDelivery Sciences International by 4.0% in the fourth quarter. Broadfin Capital LLC now owns 5,398,794 shares of the specialty pharmaceutical company’s stock worth $9,448,000 after buying an additional 210,000 shares during the period. Finally, A.R.T. Advisors LLC boosted its position in BioDelivery Sciences International by 174.8% in the fourth quarter. A.R.T. Advisors LLC now owns 98,100 shares of the specialty pharmaceutical company’s stock worth $171,000 after buying an additional 62,400 shares during the period. Institutional investors and hedge funds own 53.57% of the company’s stock.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

12 Month Chart for NASDAQ:BDSI

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.